Endogenous kynurenines as targets for drug discovery and development

Nature Reviews Drug Discovery

Volumn 1, Issue 8, 2002, Pages 609-620

  Stone, Trevor W ^a   Darlington, L Gail ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b EPSOM GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 CARBOXY 4,6 DICHLORO 3 INDOLYL)PROPIONIC ACID; 3 HYDROXYKYNURENINE; 5,7 DICHLORO 1,2,3,4 TETRAHYDRO 4 (3 PHENYLUREIDO) 2 QUINOLINECARBOXYLIC ACID; 5,7 DICHLOROKYNURENIC ACID; 7 CHLORO 1,2,5,10 TETRAHYDRO 4 HYDROXY 2 (4 METHOXY 2 METHYLPHENYL)PYRIDAZINO[4,5 B]QUINOLINE 1,10 DIONE; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; ACETYLSALICYLIC ACID; ENZYME INHIBITOR; GAVESTINEL; GLUTAMATE RECEPTOR; INDOLEPYRUVIC ACID; KYNURAMINE; KYNURENIC ACID; KYNURENINE; L 695902; L 701252; L 705022; MELATONIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NICOTINIC RECEPTOR; NITRIC OXIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; QUINOLINIC ACID; RO 618048; RPR 104632; SC 49648; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG DERIVATIVE;

BRAIN ISCHEMIA; CELL PROLIFERATION; CIRCADIAN RHYTHM; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; HUMAN; IMMUNE SYSTEM; NERVOUS SYSTEM; NEUROPROTECTION; NEUROSCIENCE; NONHUMAN; ONCOLOGY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SLEEP DISORDER; TRANQUILIZING ACTIVITY; TRYPTOPHAN METABOLISM; VASOCONSTRICTION; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DESIGN; METABOLISM; METHODOLOGY; PHARMACEUTICS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; KYNURENIC ACID; KYNURENINE; SIGNAL TRANSDUCTION; TECHNOLOGY, PHARMACEUTICAL; TRYPTOPHAN;

EID: 0036690151     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd870     Document Type: Review

References (146)

1. Peters, J. C. Tryptophan nutrition and metabolism: an overview. Adv. Exp. Med. Biol. 294, 345-358 (1991).
2. Stone, T. W. & Perkins, M. N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 72, 411-412 (1981).
3. Schwarcz, R., Whetsell, W. O. Jr & Mangano, R. M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219, 316-318 (1983).
4. Perkins, M. N. & Stone, T. W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247, 184-187 (1982).
5. Thomas, S. R. & Stocker, R. Redox reactions related to IDO and tryptophan metabolism along the kynurenine pathway. Redox Rep. 4, 199-220 (1999).
6. Pfefferkorn, E. R. Interferon-γ blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cell to degrade tryptophan. Proc. Natl Acad. Sci. USA 81, 908-912 (1984).
7. MacKenzie, C. R. et al. Growth inhibition of multiresistant enterococci by interferon-γ-activated human uro-epithelial cells. J. Med. Microbiol. 48, 935-941 (1999).
8. Carlin, J. M., Ozaki, Y., Byrne, G. I., Brown, R. R. & Borden, E. C. Interferons and IDO: role in antimicrobial and antitumour effects. Experientia 45, 535-541 (1989).
9. Rzeski, W., Turski, L. & Ikonomidou, C. Glutamate antagonists limit tumour growth. Proc. Natl Acad. Sci USA 98, 6372-6377 (2001).
10. Moffett, J. R. et al. Quinolinate immunoreactivity in experimental rat brain tumors is present in macrophages but not in astrocytes. Exp. Neurol. 144, 287-301 (1997)
11. Munn, D. H. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191-1193 (1998).
12. Thomas, S. R., Mohr, D. & Stocker, R. Nitric oxide inhibits IDO activity in IFN-γ primed mononuclear phagocytes. J. Biol. Chem. 269, 14457-14464 (1994).
13. Sekkai, D., Guittet, O., Lemaire, G., Tenu, J.-P. & Lepoivre, M. Inhibition of nitric oxide synthase expression and activity in macrophages by 3-hydroxyanthranilic acid, a tryptophan metabolite. Arch. Biochem. Biophys. 340, 117-123 (1997).
14. Stone, T. W. The neuropharmacology of quinolinic acid and kynurenic acid. Pharmacol. Rev. 45, 309-379 (1993).
15. Stone, T. W. The development and therapeutic potential of kynurenic acid and kynurenine derivatives for CNS neuroprotection. Trends Pharmacol. Sci. 21, 149-154 (2000).
16. Stone, T. W. Kynurenines in the CNS: from obscurity to clinical relevance. Progr. Neurobiol. 64, 185-218 (2001).
17. Bordelon, Y. M., Chesselet, M.-F., Nelson, D., Welsh, F. & Erecinska, M. Energetic dysfunction in quinolinic acid-lesioned rat striatum. J. Neurochem. 69, 1629-1693 (1997).
18. Baran, H. et al. Kynurenic acid influences the respiratory parameters of rat heart mitochondria. Pharmacology 62, 119-123 (2001).
19. Santamaria, A. et al. In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum. Neuroreport 12, 2693-2696 (2001)
20. Behan, W. M. H., McDonald, M., Darlington, L. G. & Stone, T. W. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br. J. Pharmacol. 128, 1754-1760 (1999).
21. Kim, J. P. & Choi, D. W. Quinolinate neurotoxicity in cortical cell culture. Neuroscience 23, 423-432 (1987).
22. Khaspekov, L., Kida, E., Victorov, I. & Mossakowski, M. J. Neurotoxic effect induced by quinolinic acid in dissociated cell culture of mouse hippocampus. J. Neurosci. Res. 22, 150-157 (1989).
23. Whetsell, W. O. Jr & Schwarcz, R. Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system. Neurosci. Lett. 97, 271-275 (1989).
24. Kerr, S. J., Armati, P. J., Guillemin, G. J. & Brew, B. J. Chronic exposure of human neurones to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. AIDS 12, 355-363 (1998).
25. Guidetti, P. & Schwarcz, R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur. J. Neurosci. 11, 3857-3863 (1999).
26. Ghorayeb, I. et al. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection. A model of early-stage striatonigral degneration. Exp. Neurol. 167, 133-147 (2001).
27. Behan, W. M. H. & Stone, T. W. Enhanced neuronal damage by co-administration of quinolinic acid and free radicals and protection by adenosine A2A receptor antagonists. Br. J. Pharmacol. 135, 1435-1442 (2002).
28. Dikranian, K. et al. Apoptosis in the developing mammalian forebrain. Neurobiol. Disease 8, 359-379 (2001).
29. Gurdon, J. B. & Bourillot, P.-Y. Morphogen gradient interpretation. Nature 413, 797-803 (2001).
30. Rezaie, P. & Male, D. Colonisation of the developing human brain and spinal cord by microglia: a review. Microscopy Res. Tech. 45, 359-382 (1999).
31. McGowan, J. E. et al. Effect of dexamethasone treatment on maturational changes in the NMDA receptor in sheep brain. J. Neurosci. 20, 7424-7429 (2000).
32. Dong-Ruyl, L., Sawada, M. & Nakano, K. Tryptophan and its metabolite, kynurenine, stimulate expression of NGF in cultured mouse astroglial cells. Neurosci. Lett. 244, 17-20 (1998).
33. Heyes, M. P., Rubinow, D., Lane, C. & Markey, S. P. Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome. Ann. Neurol. 26, 275-277 (1989).
34. Espey, M. G., Moffett, J. R. & Namboodiri, M. A. A. Temporal and spatial changes of quinolinic acid immunoreactivity in the immune system of lipopolysaccharide-stimulated mice. J. Leukocyte Biol. 57, 199-206 (1995).
35. Namboodiri, A. M. A. et al. Increased quinolinate immunoreactivity in the peripheral blood macrocytes/macrophages from SIV-infected monkeys. J. Neurovirol. 2, 433-438 (1996).
36. Heyes, M. P. et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurologic disease. Brain 115, 1249-1273 (1992).
37. Pemberton, L. A., Kerr, S. J., Smythe, G. & Brew, B. J. Quinolinic acid production by macrophages stimulated with IFN-γ, TNF-α and IFN-α. J. Int. Cytokine Res. 17, 589-595 (1997).
38. Kohler, C. et al. Quinolinic acid metabolism in the rat brain. Immunohistochemical identification of 3-hydroxyanthranilic acid oxygenase and quinolinic acid phosphoribosyl-transferase in the hippocampal region. J. Neurosci. 8, 975-987 (1998).
39. Espey M. G., Tang, Y., Morse, H. C., Moffett, J. R. & Namboodiri, M. A. A. Localisation of quinolinic acid in the murine AIDS model of retrovirus-induced immunodeficiency: implications for neurotoxicity and dendritic cell immunopathogenesis. AIDS 10, 151-158 (1996).
40. Guidetti, P., Eastman, C. L. & Schwarcz, R. Metabolism of [5-3H]-kynurenine in rat brain in vivo: evidence for the existence of a functional kynurenine pathway. J. Neurochem. 65, 2621-2632 (1995).
41. Guillemin, G. J. et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 78, 842-853 (2001).
42. Kazda, H., Taylor, N., Healy, D. & Walker, D. Maternal, umbilical and amniotic fluid concentrations of tryptophan and kynurenine after labor or cesarean section. Pediatr. Res. 44, 368-373 (1998).
43. Milart, P., Urbanska, E. M., Turski, W. A., Paszkowski, T. &. Sikorski, R. Intrapartum levels of endogenous glutamate antagonist kynurenic acid in amniotic fluid, umbilical and maternal blood. Neurosci. Res. Commun. 24, 173-178 (1999).
44. Nicholls, T., Nitsos, I. & Walker, D. W. Tryptophan metabolism in pregnant sheep: increased fetal kynurenine production in response to maternal tryptophan loading. Am. J. Obst. Gyn. 181, 1452-1460 (1999).
45. Henderson, G., Johnson, J. W. & Ascher, P. Competitive antagonists and partial agonists at the glycine modulatory site of the mouse NMDA receptors. J. Physiol. 430, 189-212 (1990).
46. Birch, P. J., Grossman, C. J. & Hayes, A. G. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur. J. Pharmacol. 154, 85-87 (1988).
47. Scharfman, H. E., Hodgkin, P. S., Lee, S.-C. & Schwarcz, R. Quantitative differences in the effects of de novo produced and exogenous kynurenic acid in rat brain slices. Neurosci. Lett. 274, 111-114 (1999).
48. Schwarcz, R. et al. Modulation and function of kynurenic acid in the immature rat brain. Adv. Exp. Med. Biol. 467, 113-123 (1999).
49. Stone, T. W. Comparison of kynurenic acid and 2-APV suppression of epileptiform activity in rat hippocampal slices. Neurosci. Lett. 84, 234-238 (1988).
50. Brady, R. J. & Swann, J. W. Suppression of ictal-like activity by kynurenic acid does not correlate with its efficacy as an NMDA receptor antagonist. Epilepsy Res. 2, 232-238 (1988).
51. Carpenedo, R. et al. Presynaptic kynrenate-sensitive receptors inhibit glutamate release. Eur. J. Neurosci. 13, 2141-2147 (2001).
52. Hilmas, C. et al. The brain metabolite kynurenic acid inhibits α7-nicotinic receptor activity and increases non-α7-nicotinic receptor expression: pathophysiological implications. J. Neurosci. 21, 7463-7473 (2001).
53. Erhardt, S., Oberg, H. & Engberg, G. Pharmacologically elevated levels of endogenous kynurenic acid prevent nicotine-induced activation of nigral dopamine neurones. Arch. Pharmacol. 363, 21-27 (2001)
54. Eastman, C. L. & Guilarte, T. R. The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem. Res. 15, 1101-1107 (1990).
55. Okuda, S., Nishiyama, N., Saito, H. & Katsuki, H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J. Neurochem. 70, 299-307 (1998).
56. Chiarugi, A., Meli, E. & Moroni, F. Similarities and differences in the neuronal death processes activated by 3-hydroxy-kynurenine and quinolinic acid. J. Neurochem. 77, 1310-1318 (2001).
57. Heyes, M. P. et al. Elevated CSF quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection. Brain Res. 124, 1033-1042 (2001).
58. Sardar, A. M. & Reynolds, G. P. Frontal cortex indoleamin-2,3-dioxygenase activity is increased in HIV-1-associated dementia. Neurosci. Lett. 187, 9-12 (1995).
59. Heyes, M. P. et al. Inter-relationships between neuroactive kynurenines, neopterin and 2-microglobulin in CSF and serum of HIV-1 infected patients. J. Neuroimmunol. 40, 71-80 (1992).
60. Beal, M. F. et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321, 168-171 (1986).
61. Beal, M. F., Ferrante, R. J., Swartz, K. J. & Kowall, N. W. Chronic quinolinic acid lesions in rats closely resemble Huntington's Disease. J. Neurosci. 11, 1649-1659 (1991).
62. A receptor changes in the substantia nigra of the rat following quinolinic acid lesions in the striatum closely resemble Huntington's disease. Neuroscience 66, 507-521 (1995).
63. Carlock, L., Walker, P. D., Shan, Y. & Gutridge, K. Transcription of the Huntington disease gene during the quinolinic acid excitotoxic cascade. Neuroreport 6, 1121-1124 (1995).
64. Schwarcz, R., Okuno, E., White, R. J., Bird, E. D. & Whetsell, W. O. Jr. 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. Proc. Natl Acad. Sci. USA 85, 4079-4081 (1988).
65. Connick, J. H., Carla, V., Moroni, F. & Stone, T. W. Increase in kynurenic acid in Huntington's disease motor cortex. J. Neurochem. 52, 985-987 (1989).
66. Beal, M. F. et al. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J. Neurol. Sci. 108, 80-87 (1992).
67. Jauch, D. et al. Dysfunction of brain kynurenic acid metabolism in Huntington's disease: Focus on kynurenine aminotransferases. J. Neurol. Sci. 130, 39-47 (1995).
68. Pearson, S. J. & Reynolds, G. P. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. Neurosci. Lett. 144, 199-201 (1992).
69. Guidetti, P., Reddy, P. H., Tagle, D. A. & Schwarcz, R. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model. Neurosci Lett. 283, 233-235 (2000).
70. Hansson, O. et al. Mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl Acad. Sci. USA 96, 8727-8732 (1999).
71. MacGibbon, G. A. et al. Immediate-early gene response to methamphetamine, haloperidol and quinolinic acid is not impaired in Huntington's disease transgenic mice. J. Neurosci. Res. 67, 372-378 (2002).
72. Widner, B. et al. Tryptophan degradation and immune activation in Alzheimer's disease. J. Neural Transm. 107, 343-353 (2000).
73. Darlington, L. G. et al. Concentrations of kynurenine pathway metabolites in patients with Huntington's disease. Soc. Neurosci. Abstr. (in the press).
74. Widner, B. et al. Degradation of tryptophan in neurodegenerative disorders. Adv. Exp. Med. Biol. 467, 133-138 (1999).
75. Baran, H., Cairns, N., Lubec, B. & Lubec, G. Increased kynurenic acid levels and decreased brain kynurenine aminotransferase I in patients with Down syndrome. Life Sci. 58, 1891-1899 (1996).
76. Savvateeva, E. et al. Age-dependent memory loss, synaptic pathology and altered brain plasticity in the Drosophila mutant cardinal accumulating 3-hydroxykynurenine. J. Neural Transm. 107, 581-601 (2000).
77. Heyes, M. P. et al. Poliovirus induces IDO and quinolinic acid synthesis in macaque brain. FASEB J. 6, 2977-2989 (1992).
78. Halperin, J. J. & Hayes, M. P. Neuroactive kynurenines in Lyme borreliosis. Neurology 42, 43-50 (1992).
79. Sanni, L. A. et al. Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and non-cerebral malaria. Am. J. Pathol. 152, 611-619 (1998).
80. Heyes, M. P. & Nowak, T. S. Jr. Delayed increases in regional brain quinolinic acid follow transient ischemia in the gerbil. J. Cereb. Blood Flow Metab. 10, 660-667 (1990).
81. Baratte, S. et al. Temporal and spatial changes of quinolinic acid immunoreactivity in the gerbil hippocampus following transient cerebral ischemia. Mol. Brain Res. 59, 50-57 (1998).
82. Blight, A. R., Leroy, E. C. & Heyes, M. P. Quinolinic acid accumulation in injured spinal cord: time course, distribution and species differences between rat and guinea-pig. J. Neurotrauma 14, 89-98 (1997).
83. Sinz, E. H. et al. Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans. J. Cereb. Blood Flow Metab. 18, 610-615 (1998).
84. Baran, H. et al. Increased kynurenic acid in the brain after neonatal asphyxia. Life Sci. 69, 1249-1256 (2001).
85. Ceresoli-Borroni, G. & Schwarcz, R. Neonatal asphyxia in rats: acute effects on cerebral kynurenine metabolism. Pediatr. Res. 50, 231-235 (2001).
86. Dang, Y., Dale, W. E & Brown, O. R. Comparative effects of oxygen on IDO and TDO of the kynurenine pathway. Free Radical Biol. Med. 28, 615-624 (2000).
87. Issa, F. et al. A multidimensional approach to analysis of CSF biogenic amines in schizophrenia. II. Correlations with psychopathology. Psychiatr. Res. 52, 251-258 (1994).
88. Erhardt, S. et al. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 313, 96-98 (2001).
89. Chiarugi, A., Cozzi, A., Ballerini, C., Massacesi, L. & Moroni, F. Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis. Neuroscience 102, 687-695 (2001).
90. Maloney, A. M., St Claire Morgan, O., Widner, B., Werner, E. R. & Fuchs, D. CNS activation of the IDO pathway in human T cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J. Infect. Dis. 181, 2037-2040 (2000).
91. Baron, B. M. et al. Potent indole- and quinoline-containing NMDA antagonists acting at the strychnine-insensitive glycine binding site. J. Pharmacol. Exp. Ther. 262, 947-956 (1992).
92. Leeson, P. D. et al. Kynurenic acid derivatives - structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the NMDA receptor. J. Med. Chem. 34, 1243-1252 (1991).
93. Harrison B. L., Baron, B. M., Cousino, D. M. & McDonald, I. A. 4-[(Carboxymethyl)oxy]- and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid: new antagonists of the strychnine-insensitive glycine binding site on the NMDA receptor complex. J. Med. Chem. 33, 3130-3132 (1990).
94. Farr, R. A., Nyce, P. L. & Harrison, B. L. Heterocycle substituted bropenoic acid derivatives as NMDA antagonists. Patent WO9613501 (1996).
95. Cugola, A. & Gavaraghi, G. Indole antagonists of excitatory amino acids. British patent GB2266091 (1993).
96. Jackson, P. F. et al. Synthesis and biological activity of a series of 4-aryl substituted benz[b]azepines: antagonists at the strychnine-insensitive glycine site. Bioorg. Med. Chem. Lett. 5, 3097-3100 (1995).
97. Boireau, A. et al. Neuroprotective effects of RPR104632, a novel antagonist at the glycine site of the NMDA receptor. Eur. J. Pharmacol. 300, 237-246 (1996).
98. Gottschlich, R., Leibrock, J., Noe, C., Berger, M. & Buchstaller, H.-P. Thienopyridone derivatives, their preparation and their use as NMDA-receptor antagonists. European patent EP717044 (1996).
99. Aloup, J. C. et al. 4-hydroxy-3-phenyl-indeno(1,2-B)pyridine-2(1H)-one derivatives as NMDA antagonists. Patent WO9602536 (1996).
100. Chapman, A. G. et al. Anticonvulsant activity of a novel NMDA glycine site antagonist, MDL 104,653, against kindled and sound-induced seizures. Eur. J. Pharmacol. 274, 1-3 (1995).
101. Kulagowski, J. J. Glycine-site NMDA antagonists: an update. Exp. Opin. Ther. Pat. 6, 1069-1079 (1996).
102. Takano, K. et al. Glycine site antagonists attenuate infarct size in experimental focal ischaemia: postmortem and diffusion mapping studies. Stroke 28, 1255-1263 (1997).
103. Harris, C. A. et al. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br. J. Pharmacol. 124, 391-399 (1998).
104. Wu, H.-Q. et al. Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo. Neuroscience 97, 243-251 (2000).
105. Guidetti, F., Wu, H.-Q. & Schwarcz, R. In situ produced 7-chlorokynurenate provides protection against quinolinate and malonate-induced neurotoxicity in the rat striatum. Exp. Neurol. 163, 123-130 (2000).
106. Wu, H.-Q., Lee, S.-C. & Schwarcz, R. Systemic administration of 4-chlorokynurenine prevents quinolinic acid neurotoxicity in the rat hippocampus. Eur. J. Pharmacol. 390, 267-274 (2000).
107. Connick, J. H. et al. Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. Gen. Pharmacol. 23, 235-239 (1992).
108. Russi, P. et al. Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions. J. Neurochem. 59, 2076-2080 (1992).
109. Chiarugi, A., Carpenedo, R. & Moroni, F. Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and kynurenase. J. Neurochem. 67, 692-698 (1996).
110. Cozzi, R., Carpenedo, R. & Moroni, F. Kynurenine hydroxylase inhibitors reduce ischaemic brain damage: studies with (m-nitrobenzoyl)alanine and 3,4-dimethoxy-[N-4-(nitrophenyl)thiazol-2-yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global ischaemia. J. Cereb. Blood Flow Metab. 19, 771-777 (1999).
111. Speciale, C. et al. (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur. J. Pharmacol. 315, 263-267 (1996).
112. Rover, S., Cesura, A. M., Hugenin, P., Kettler, R. & Szente, A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J. Med. Chem. 40, 4378-4385 (1997).
113. Heidempergher, F. et al. Pyrrolo[3,2c]quinoline derivatives: a new class of kynurenine-3-hydroxylase inhibitors. II Farmaco 54, 152-160 (1999).
114. Giordani, A. et al. 4-Phenyl-4-oxo-butanoic acid derivatives as inhibitors of kynurenine-3-hydroxylase. Bioorg. Med. Chem. Lett. 8, 2907-2912 (1998).
115. Chiarugi, A. & Moroni, F. Quinolinic, acid formation in immuno-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[N-4-(3-nitrophenyl)thiazol-2-yl]benzenesulphonamide (Ro61-8048), two potent and selective inhibitors of kynurenine hydroxylase. Neuropharmacology 38, 1225-1233 (1999).
116. Ross, F. C., Botting, N. P. & Leeson, P. D. Synthesis of phosphinic acid transition state analogues for the reaction catalysed by kynureninase. Bioorg. Med. Chem. Lett. 6, 2643-2646 (1996).
117. Fitzgerald, D. H., Muirhead, K. M. & Botting, N. G. A comparative study of the inhibition of human and bacterial kynureninase by novel bicyclic kynurenine analogues. Bioorg. Med. Chem. 9, 983-999 (2001).
118. Walsh, J. L., Todd, W. P., Carpenter, B. K. & Schwarcz, R. 4-Halo-3-hydroxyanthranilic acids: potent competitive inhibitors of 3-hydroxyanthranilic acid oxygenase in vitro. Biochem. Pharmacol. 42, 985-990 (1991).
119. Luthman, J., Radesater A.-C. & Oberg, C. Effects of the 3-hydroxyanthranilic acid analogue NCR-631 on anoxia-, IL-1β- and UPS-induced hippocampal pyramidal cell loss in vitro. Amino Acids 14, 263-269 (1998).
120. Forrest, C. M., Kennedy, A., Stone, T. W. & Darlington, L. G. in Proceedings of the 10th Meeting of ISTRY (ed. Costa, C. V. L.) (Plenum, New York) (in the press).
121. Skerry, T. M. & Genever, P. G. Glutamate signalling in non-neuronal tissues. Trends Pharmacol. Sci. 22, 174-181 (2001).
122. Weaver, C. D. et al. Differential expression of glutamate receptor subtypes in rat pancreatic islets. J. Biol. Chem. 271, 12977-12984 (1996).
123. Okamoto, H. Effect of quinaldic acid and its relatives on insulin release from isolated Langerhans islets. Acta Vitaminol. Enzymol. 29, 227-230 (1975).
124. Kotake, Y., Ueda, T., Mori, T., Igaki, S. & Hattori, M. Abnormal tryptophan metabolism and experimental diabetes by xanthurenic acid. Acta Vitaminol. Enzymol. 29, 236-240 (1975).
125. Hattori, M., Kotake, Y. & Kotake, Y. Studies on the urinary excretion of xanthurenic acid in diabetics. Acta Vitaminol. Enzymol. 6, 221-228 (1984).
126. Takeuchi, E. & Shibata, X. Kynurenine metabolism in vitamin B6 deficient rat liver after tryptophan injection. Biochem. J. 220, 693-699 (1984).
127. Goldstein, L. E. et al. 3-Hydroxykynurenine and 3-hydroxy-anthranilic acid generate hydrogen peroxide and promote α-crystallin cross-linking by metal ion reduction. Biochemistry 39, 7266-7275 (2000).
128. Varga, J., Yufit, T., Hitraya, T. & Brown, R. R. Control of extracellular matrix degradation by interferon-γ. The tryptophan connection. Adv. Exp. Med. Biol. 398, 143-148 (1996).
129. Moroni, F., Luzzi, S., Franchi-Micheli, S. & Ziletti, L. The presence of NMDA receptors for glutamic acid in the guinea-pig myenteric plexus. Neurosci. Lett. 68, 57-62 (1986).
130. Forrest, C. M. et al. Purine, kynurenine, and lipid peroxidation levels in inflammatory bowel disease. J. Biomed. Sci. (in the press).
131. Patton, A. J. et al. Expression of an NMDA type receptor by human and rat osteoblasts. Bone 22, 645-649 (1998).
132. Itzstein, C. et al. Specific antagonists of NMDA receptors prevent osteoclast sealing zone formation required for bone resorption. Biochem. Biophys. Res. Commun. 268, 201-209 (2000).
133. Gill, S. K., Mueller, R. W., McGuire, P. F. & Pulido, O. M. Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity. Toxicol. Pathol. 28, 277-284 (2000).
134. Goldstein, L. E. et al. 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote α-crystallin cross-linking by metal ion reduction. Biochemistry 39, 7266-7275 (2000).
135. Aquilina, J. A., Carver, J, A. & Truscott, R. J. W. Elucidation of a novel polypeptide cross-link involving 3-hydroxy-kynurenine. Biochemistry 38, 11455-11464 (1999).
136. Moroni, F., Lombardi, G., Moneti, G. & Aldinio, C. The excitotoxin quinolinic acid is present in the brain of several animal species and its cortical content increases during the ageing process. Neurosci. Lett. 47, 51-55 (1984).
137. Johnson, T. D. & Clarke, D. E. in Quinolinic acid and the Kynurenines (ed. Stone, T. W.) 213-228 (CRC Press, Boca Raton, 1989).
138. Charlton, K. G., Johnson, T. D., Hamed, A. T. & Clarke, D. E. Cardiovascular actions of kynuramine and 5-hydroxy-kynuramine in pithed rats. J. Neural Transm. 57, 199-209 (1983).
139. Watts, S. W., Gilbert, L. & Webb, R. C. 5HT-2(B) receptor mediates contraction in the mesenteric artery of mineralocorticoid hypertensive rats. Hypertension 26, 1056-1059 (1995).
140. McCormack, J. K., Beitz, A. J. & Larson, A. A. Autoradiographic localization of tryptamine sites in the rat and dog CNS. J. Neurosci. 6, 94-101 (1986).
141. Kelly, R. W., Amato, F. & Seamark, R. F. N-Acetyl-5-methoxykynurenamine, a brain metabolite of melatonin, is a potent inhibitor of prostaglandin biosynthesis. Biochem. Biophys. Res. Commun. 121, 372-379 (1984).
142. Ramsay, R. R., Tan, A. K. & Weyler, W. Kinetic properties of cloned human liver monoamine oxidase A. J. Neural Transm. 41 (Suppl.), 17-26 (1994).
143. Franchi, A. M., Gimeno, M. F., Cardinali, D. P. & Vacas, M. I. Melatonin, 5-methoxytryptamine and some of their analogues as cyclo-oxygenase inhibitors in rat medial basal hypothalamus. Brain Res. 405, 384-388 (1987).
144. Worthen, D. R., et al. Endogenous indoles as novel polyamine site ligands at the NMDA receptor complex. Brain Res. 890, 343-346 (2001).
145. Leon, J. et al. Modification of nitric oxide synthase activity and neuronal response in rat striatum by melatonin and kynurenine derivatives. J. Neuroendocrinol. 10, 297-302 (1998).
146. Politi, V., De Luca, G., Gallai V. & Comin, M. Clinical experiences with the use of indole-3-pyruvic acid. Adv. Exp. Med. Biol. 467, 227-232 (1999).